Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

C.C.B. Post*, J.W.M. Mens, M.A.D. Haverkort, F. Koppe, I.M. Jurgenliemk-Schulz, A. Snyers, E.M.A. Roeloffzen, E.E. Schaake, A. Slot, T.C. Stam, J.C. Beukema, H.A. van den Berg, L.C.H.W. Lutgens, H.W. Nijman, C.D. de Kroon, J.R. Kroep, A.M. Stiggelbout, C.L. Creutzberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalGynecologic Oncology
Volume161
Issue number3
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • Endometrial cancer
  • Patient preferences
  • Clinician preferences
  • Adjuvant chemotherapy
  • Chemoradiotherapy
  • Decision-making
  • QUALITY-OF-LIFE
  • BREAST-CANCER
  • SYSTEMIC TREATMENT
  • CHEMOTHERAPY
  • VALIDATION
  • THERAPY
  • IMPACT

Cite this